We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Anti-HEV Assays Evaluated for Diagnosing Acute Hepatitis E Infections

By LabMedica International staff writers
Posted on 04 Dec 2013
The performance of two anti-HEV IgG and IgM assays were assessed for diagnosing acute HEV infections in immunocompromised patients.

Hepatitis E virus is an emerging concern in immunocompromised patients, who may become chronically infected. More...
No data were available for immunocompromised patients, who might not mount a good antibody response to HEV and might thus test negative for anti-HEV antibodies. The two anti-HEV assays evaluated in the study, published in the Journal of Clinical Virology online ahead of print October 15, 2013, were those from Adaltis and Wantai, the two main serological assays employed in Europe, specifically: EIAgen HEV IgG and IgM kits (Adaltis; Eurobio, France), based on synthetic antigens encoded by the ORF2 and ORF3 genes of HEV1 and HEV2; and the HEVIgM and IgG ELISA 3.0 Wantai kits (Wantai Biological Pharmacy Enterprise Co.; China), based on a recombinant HEV1 antigen, pE2. Tests were performed as recommended by the manufacturers.

Specificities were estimated by testing samples from 2 to 3 year-old children and blood donors and sensitivities were estimated by testing 40 immunocompromised patients acutely infected. Both anti-HEV IgM assays were highly specific (99.6% and 100%). The sensitivity of the Adaltis was 87.5%, and that of Wantai was 85%. The specificities of anti-HEV IgG Wantai (97.8%) and Adaltis tests (89.5%, = 0.1) were similar but the Wantai test was more sensitive (45%) than the Adaltis test (15%, < 0.001). None of the samples was anti-HEV IgM negative and IgG positive.

The authors, led by Dr. Florence Abravanel of the Centre Hospitalier Universitaire de Toulouse (University Hospital Center of Toulouse; Toulouse, France), concluded that these anti-HEV IgM assays performed well in immunosuppressed patients with acute hepatitis E and can be used as first line virological tools. Testing for anti-HEV IgG and IgM simultaneously at the acute phase did not improve the diagnostic performance. In contrast, molecular detection of HEV RNA appears essential to exclude an HEV infection in patients who are negative for anti-HEV IgM and to assess the evolution of hepatitis E three months thereafter.

Related Links:

Centre Hospitalier Universitaire de Toulouse



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Automated Cell Culture Chemistry Analyzer
BioProfile FLEX2 Basic
New
Integrated Biochemical & Immunological System
Biolumi CX8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.